Taquicardia ventricular maligna na acromegalia
relato de caso
Palavras-chave:
Taquicardia ventricular, Acromegalia, Relatos de casos, Desfibriladores implantáveis, Arritmias cardíacasResumo
CONTEXTO: As complicações cardiovasculares são a principal causa de morte em pacientes com acrome-galia, e a morte súbita tem sido associada a taquiarritmias ventriculares. Em outros pacientes com risco de vida por taquiarritmias ventriculares malignas, a aplicação cirúrgica de um cardioversor-desfibrilador implantável (CDI) provou ser altamente eficaz na redução das taxas de morte súbita. RELATO DE CASO: O presente artigo relata o caso de um paciente acromegálico de 50 anos de ida-de e do sexo masculino, que apresentava sintomas de síncope induzida por taquicardia ventricular. Foi implantado cirurgicamente nesse paciente um CDI e na mesma intervenção cirúrgica foi completa-mente removido um adenoma hipofisário responsável pela acromegalia. A cirurgia foi bem-sucedida e o paciente deixou de sofrer de arritmias ventriculares. Durante seis meses de acompanhamento, não se documentaram, nesse paciente, episódios arrítmicos. CONCLUSÃO: A taquiarritmia ventricular maligna pode ser efetivamente controlada em pacientes com acromegalia pela implantação de um CDI combinado com a remoção cirúrgica do adenoma hipofisário.
Downloads
Referências
Palmeiro CR, Anand R, Dardi IK, et al. Growth hormone and the cardiovascular system. Cardiol Rev. 2012;20(4):197-207.
Albat B, Leclercq F, Serre I, et al. Heart transplantation for terminal congestive heart failure in an acromegalic patient. Eur Heart J. 1993;14(11):1572-5.
Maffei P, Martini C, Milanesi A, et al. Late potentials and ventricular arrhythmias in acromegaly. Int J Cardiol. 2005;104(2):197-203.
Tan TT, Gangaram HB, Yusoff K, Khalid B. Third degree heart block in acromegaly. Postgrad Med J. 1992;68(799):389.
Maffei P, Martini C, Mioni R, et al. Emergency pacemaker implantation in acromegaly. Int J Cardiol. 2004;97(1):161-4.
Devoitille A, Beckers A, Piérard LA. Le cas clinique du mois. Complications cardiaques de l’acromégalie: cas rare de cardiopathie dilatée [Clinical case of the month. Cardiac complications of acromegaly: a rare cause of dilated cardiomyopathy]. Rev Med Liege. 2012;67(4):174-8.
Yokota F, Arima H, Hirano M, et al. Normalisation of plasma growth hormone levels improved cardiac dysfunction due to acromegalic cardiomyopathy with severe fibrosis. BMJ Case Rep. 2010;19:2010.
Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(10):e385-484.
Abe N, Matsunaga T, Kameda K, et al. Increased level of pericardial insulin-like growth factor-1 in patients with left ventricular dysfunction and advanced heart failure. J Am Coll Cardiol. 2006;48(7):1387-95.
Jayasena CN, Comninos AN, Clarke H, et al. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly. Clin Endocrinol (Oxf ). 2011;75(2):220-5.
Kahaly G, Olshausen KV, Mohr-Kahaly S, et al. Arrhythmia profile in acromegaly. Eur Heart J. 1992;13(1):51-6.
Rodrigues EA, Caruana MP, Lahiri A, et al. Subclinical cardiac dysfunction in acromegaly: evidence for a specific disease of heart muscle. Br Heart J. 1989;62(3):185-94.
Colao A, Pivonello R, Grasso LF, et al. Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study. Eur J Endocrinol. 2011;165(5):713-21.
Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25(1):102-52.
Beijerink NJ, Dieleman SJ, Kooistra HS, Okkens AC. Low doses of bromocriptine shorten the interestrous interval in the bitch without lowering plasma prolactin concentration. Theriogenology. 2003;60(7):1379-86.
Cronin MJ, Thorner MO, Hellmann P, Rogol AD. Bromocriptine inhibits growth hormone release from rat pituitary cells in primary culture. Proc Soc Exp Biol Med. 1984;175(2):191-5.
Lugo G, Pena L, Cordido F. Clinical manifestations and diagnosis of acromegaly. Int J Endocrinol. 2012;2012:540398.
Biller BM, Colao A, Petersenn S, Bonert VS, Boscaro M. Prolactinomas, Cushing’s disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. BMC Endocr Disord. 2010;10:10.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
